Navigation Links
Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
Date:9/17/2007

of 200 mg and 500 mg) receiving PS433540 or placebo once daily for 28 days. Following the four week treatment period, investigators will evaluate the patients' change from baseline in mean 24-hour ambulatory systolic blood pressure; mean 24-hour ambulatory diastolic blood pressure; and mean seated systolic and diastolic blood pressure.

"We are very pleased to have initiated this important Phase 2a concept validation study of PS433540 approximately six months ahead of our original clinical development timeline," said Les Browne, Ph.D., President and Chief Executive Officer of Pharmacopeia. "The goal of this study is to prove that PS433540 lowers blood pressure in hypertensive patients."

Results from the initial Phase 1 trial of PS433540, a single ascending dose (SAD) study, indicated that the compound was well tolerated at all six doses administered ranging from 20 mg to 1,000 mg and that the compound has a half-life that is consistent with once daily administration. In the Phase 1 multiple ascending dose (MAD) study, 4 dose levels ranging from 50 mg to 500 mg did not produce safety or tolerability issues. Consistent with prior guidance, Pharmacopeia expects to report results of an on-going Phase 1 angiotensin II challenge study in September or early in the fourth quarter; and initiate a Phase 1 endothelin challenge study later this year. These studies are designed to evaluate the dual pharmacology of PS433540 in healthy individuals.

"We are approaching this Phase 2a study with great anticipation as it is designed to provide us with important initial indications regarding PS433540's therapeutic potential in patients with cardiovascular disease," stated Rene Belder, M.D., Pharmacopeia's Vice President of Clinical and Regulatory Affairs.

ABOUT PHARMACOPEIA

Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The company has a broad portfolio advancing toward clinical validation,
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 5, 2015 BioLineRx (NASDAQ: ... dedicated to identifying, in-licensing and developing promising therapeutic ... underwritten public offering of American Depositary Shares ("ADSs"), ... All of the ADSs in the offering are ... JMP Securities is acting as sole book-running manager ...
(Date:3/5/2015)... Deutschland, 5. März 2015  Die amerikanische ... deutsche biopharmazeutische Unternehmen CureVac geben heute bekannt, ... Millionen US-Dollar) in CureVac investiert. CureVac ist ... Messenger-RNA (mRNA). Auf Basis dieses Moleküls entwickelt ... Krankheiten und zum Schutz vor Infektionskrankheiten. ...
(Date:3/5/2015)... March 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... quarter ended January 31, 2015 on Thursday, March 12 before ... the results at 11:00 AM ET. To ... to 10 minutes before the beginning of the call. If ... call will be available from Thursday, March 12, 2015 through ...
Breaking Medicine Technology:BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
... BEIJING , July 12 ... "Company") (NYSE: CCM ), the,operator of the largest ... today announced that effective as of July 1, 2010 ... for the operation of Chang,An,Hospital,s cancer treatment facilities by acquiring ...
... weeks beginning July 12 , ecoSTORE USA ,s elite team of Ecovisors will give ... select Duane Reade drug stores in New York City .  Ecovisors will also ... Nasty Ch e mic a l s™ ... , , ecoSTORE ...
Cached Medicine Technology:Concord Medical Enters into Joint Venture Agreement with Chang'An Hospital 2Concord Medical Enters into Joint Venture Agreement with Chang'An Hospital 3Concord Medical Enters into Joint Venture Agreement with Chang'An Hospital 4Ecovisors to Advise Duane Reade Shoppers 2Ecovisors to Advise Duane Reade Shoppers 3
(Date:3/6/2015)... La (PRWEB) March 06, 2015 Many ... function despite medical therapy. If you (or someone you ... to knee osteoarthritis, you may be interested in the ... Covington Orthopedic announced today that he is one of ... Cytori Therapeutics to begin enrolling subjects as part of ...
(Date:3/6/2015)... 06, 2015 Magellan Rx Management’s 2014 ... source for key trends and statistics on one of ... Executives from Magellan Rx Management will discuss key findings ... Your Hidden Specialty Drug Spend,” a complimentary March 19 ... , Specialty drug spend makes up more than a ...
(Date:3/6/2015)... March 06, 2015 Utilizing the latest ... rapidly reach their ideal weight has enabled Diet Doc ... to their already impressive collection of fat loss enhancement ... clients special promotions and savings to help people throughout ... This promotion is especially appealing to new clients ...
(Date:3/6/2015)... TX (PRWEB) March 06, 2015 Yisrayl ... in Abilene, Texas, has released a new publication explaining ... working. , The article titled “Microorganisms Do ... document explaining how tiny microorganisms were created and designed ... is aware of some of the functions of these ...
(Date:3/6/2015)... March 06, 2015 You Wealth ... created a unique ‘energy’ experiment to determine if ... , After quick ‘5 -7 minute’ remote ... 150+ countries reported their life improving - often ... positive results. , According to research, respondents saw ...
Breaking Medicine News(10 mins):Health News:Kevin Darr, M.D. is Now Enrolling Patients in a New FDA-Approved Clinical Trial Evaluating Adipose-Derived Regenerative Cells in the Treatment of Knee Osteoarthritis 2Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 3Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 4Health News:Yisrayl Hawkins Tells Scientists Exactly What Makes Life Function Properly in New Publication 2Health News:250,000+ Person ‘Remote Energy’ Event has 94.2% of Respondents saying “Life Got Better” 2
... on Certain Products Expanded to Retail LevelST. LOUIS, Feb. 3 ... KVa ; KVb), is issuing a voluntary ... on certain products. The recall on the products listed ... is now being expanded to the retail level. The ...
... for Improving Cancer Care Access, Efficiency and Quality; ... NetworkWASHINGTON, Feb. 3 /PRNewswire-USNewswire/ -- The ... one of the nation,s largest cancer treatment and ... adopted its Principles for Reforming Cancer Care, designed ...
... 2009) Green tea products have become regarded as ... of its benefit against a variety of diseases, including ... green tea may counteract the anticancer effects of one ... be contraindicated for patients taking this medicine to ensure its ...
... to popular assumptions about the health benefits of green ... have found that the widely used supplement renders a ... cell lymphoma completely ineffective in treating cancer. , ... tea extract (GTE) called EGCG destroys any anticancer activity ...
... 3 VirtualScopics, Inc.,(Nasdaq: VSCP ), a ... that Mr. Jeff Markin, the company,s chief executive,officer, will ... Annual,BIO CEO & Investor Conference at the Waldorf Astoria ... Tuesday, February 10, 2009 at 3:45pm EST. , ...
... prescribed physical activity, survey finds, , , TUESDAY, Feb. 3 (HealthDay ... with and alleviate chronic neck and back pain, a new ... as often as they should. , Less than half ... had seen a physician, chiropractor or physical therapist in the ...
Cached Medicine News:Health News:ETHEX Corporation Issues Voluntary Nationwide Recall 2Health News:US Oncology Adopts Principles for Reforming Cancer Care 2Health News:US Oncology Adopts Principles for Reforming Cancer Care 3Health News:Green tea may negate the effects of a common cancer therapy 2Health News:Green tea may negate the effects of a common cancer therapy 3Health News:USC study finds that green tea blocks benefits of cancer drug 2Health News:VirtualScopics to Present at 11th Annual BIO CEO & Investor Conference 2Health News:Are We Exercising Pain Away? Not So Much. 2
... Pulsavac Wound Debridement System ... for pulsatile irrigation,and debridement. ... range of fluid pressure ... lavage to a penetrating ...
... Amsco 3085 SP Surgical Table provides state-of-the-art ... now be networked with the HERMES Control ... Stryker Endoscopy) to allow the surgeon direct ... surgeon uses either simple voice commands or ...
... The ASC 2000 is ... care table, meeting good manufacturing ... regulatory requirements. It provides electro-hydraulic ... accessories for all ambulatory surgical ...
... The hands play an important part ... traumatic impairments and rheumatic changes can cause ... developing of the finger-joint prostheses was to ... reproduce the natural function as nearly possible.,The ...
Medicine Products: